@article{article, title = {{SOGUG-NEOWIN: A phase 2, open-label, multi-centre, multi-national interventional trial evaluating the efficacy and safety of erdafitinib (ERDA) monotherapy and ERDA and cetrelimab (CET) as neoadjuvant treatment in patients with cisplatin-ineligible muscle-invasive bladder cancer (MIBC) whose tumours express FGFR gene alterations.}}, publisher = {{American Society of Clinical Oncology (ASCO)}}, url = {{http://dx.doi.org/10.1200/jco.2024.42.16_suppl.tps4623 }}, year = {{2024}}, month = {{6}}, author = {{Hussain SA and Loriot Y and de Velasco G and Necchi A}}, doi = {{10.1200/jco.2024.42.16_suppl.tps4623}}, volume = {{42}}, journal = {{Journal of Clinical Oncology}}, issue = {{16_suppl}}, pages = {{TPS4623-TPS4623}}, note = {{Accessed on 2024/12/21}}}